- active not recruitingPHASE3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study is looking at a new medicine called resmetirom for people with a type of liver scarring called NASH cirrhosis. It aims to see if the medicine can prevent serious liver problems or death over about three years, compared to a dummy pill.
United States · Belgium · Canada - active not recruiting
LITMUS Imaging Study
This study looks at new ways to check liver health in people with fatty liver disease (NAFLD) without taking a biopsy. It uses special scans to see how well these new checks work compared to traditional methods and how liver disease changes over time.
United States · Finland · France - recruiting
The European NAFLD Registry
This study aims to understand fatty liver disease (NAFLD) better. Researchers collect information and samples from patients across Europe to find new ways to detect and monitor the disease, especially how it progresses from fatty liver to more serious conditions like fibrosis.
Belgium · Finland · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.
This study is testing a new medicine, ALY688ER, for people with fatty liver disease (NASH). It's given by injection to healthy overweight or obese adults to see if it's safe and how the body handles it as a first step in its development.
Bulgaria